lobbying_activities: 3488251

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3488251	16ca5dd8-0fdb-4621-a443-49eedd19fc02	Q4	MARSHALL & POPP, LLC	401105121	CSL BEHRING	2025	fourth_quarter	PHA	Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2026-01-16T10:42:23-05:00